{
  "id": 1577657,
  "title": "Oncoclínicas Q2 2026 slides: cash flow rebounds amid supply crisis",
  "url": "https://urgent.news/2026/08/17/oncoclinicas-q2-2026-slides-cash-flow-rebounds-amid-supply-crisis",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T22:30:22.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/oncoclinicas-q2-2026-slides-cash-flow-rebounds-amid-supply-crisis-93CH-4864074"
  },
  "original_language": "en",
  "account": null,
  "summary": "Oncoclínicas, Brazil's leading oncology care provider, reported Q2 2026 results on August 17, revealing the significant impact of a medication supply crisis while also showcasing signs of operational stabilization. The company's shares surged nearly 30% to $1.00 following the presentation, driven by positive adjusted EBITDA and operating cash flow despite a 26% year-over-year revenue decline. The main challenges came from medication shortages that disrupted patient care, with gross revenue falling to R$ 1.23 billion in the quarter, down from R$ 1.66 billion in the same period last year. However, the company secured a R$ 150 million private financing agreement to help normalize medication supply and set the stage for recovery.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}